Nepafox

Brief title: Nepafox
Design: A randomized, multicentre phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in patients with resectable pancreatic cancer.
No of patients: 126 (phase II)
Status: Under preparation

Double blind phase II/III study to determine the overal survival as the primary endpoint. Secondary endpoints are the progression free survival and the mortality/morbidity.

LKP:
Wael Hozaeel
Krankenhaus Nordwest GmbH
Steinbacher Hohl 2-26
60488 Frankfurt/Main